摘要
目的探讨抗结核方案联合抗病毒方案治疗肺结核合并E抗原阳性慢性乙肝病毒携带患者的临床疗效。方法选取2016年8月至2020年2月于本院治疗的89例肺结核合并E抗原阳性慢性乙肝病毒携带患者作为研究对象,按随机数字表法分为A组(n=44)和B组(n=45)。A组采用抗结核方案进行治疗,B组在A组基础上联合抗病毒方案治疗。比较两组治疗前后血清乙肝病毒载量、乙型肝炎E抗原(HBeAg)水平、肝功能指标情况、治疗后肝损伤情况及HBeAg转阴率。结果治疗后,B组HBeAg、血清乙肝病毒载量水平均低于A组,差异有统计学意义(P<0.05);治疗后,B组总胆红素、丙氨酸氨基转移酶及天门冬氨酸氨基转移酶水平均高于A组,差异有统计学意义(P<0.05)。B组肝损伤发生率为6.67%,低于A组的25.00%,差异有统计学意义(P<0.05);B组HBeAg转阴率为86.67%,高于A组的47.73%,差异有统计学意义(P<0.05)。结论抗结核方案联合抗病毒方案治疗肺结核合并E抗原阳性慢性乙肝病毒携带患者临床疗效显著,可明显减轻肝损伤,值得临床推广应用。
Objective To explore the clinical efficacy of anti-tuberculosis and anti-viral regimens in patients with pulmonary tuberculosis and E antigen-positive chronic hepatitis B virus carriers.Methods The 89 patients with pulmonary tuberculosis and E antigen-positive chronic hepatitis B virus treated in our hospital from August 2016 to February 2020 were selected as the research subjects and they were divided into group A(n=44)and group B(n=45)according to the random number table method.Group A was treated with anti-tuberculosis regimen,and group B was treated with anti-viral regimen on the basis of group A.The serum hepatitis B virus load,hepatitis Be antigen(HBeAg)level,liver function index,liver damage after treatment and HBeAg negative rate were compared between the two groups.Results After treatment,the levels of HBeAg and serum hepatitis B virus load in group B were lower than those in group A,the difference was statistically significant(P<0.05).After treatment,the levels of total bilirubin,alanine aminotransferase and aspartate aminotransferase in group B were higher than those in group A,and the difference was statistically significant(P<0.05).The incidence of liver damage in group B was 6.67%,which was lower than 25.00%in group A,the difference was statistically significant(P<0.05).The HBeAg negative rate in group B was 86.67%,which was higher than 47.73%in group A,the difference was statistically significant(P<0.05).Conclusion The anti-tuberculosis regimen combined with anti-viral regimen in patients with pulmonary tuberculosis and E antigenpositive chronic hepatitis B virus has a significant clinical effect,which can significantly reduce liver damage,is worth of clinical promotion.
作者
肖琴美
邱强
XIAO Qinmei;QIU Qiang(Department of Infectious Diseases,Yuanmou People's Hospital,Chuxiong,Yunnan,651300,China;Department of Internal Medicine,Yuanmou People's Hospital,Chuxiong,Yunnan,651300,China)
出处
《当代医学》
2022年第16期88-90,共3页
Contemporary Medicine
关键词
肺结核
E抗原阳性
慢性乙肝病毒
携带者
抗结核方案
抗病毒方案
Tuberculosis
E antigen positive
Chronic hepatitis B virus
Carrier
Anti-tuberculosis regimen
Anti-viral regimen
